SYK and diffuse large B-cell lymphoma: Similar results were obtained with the more selective SYK inhibitor entospletinib, which showed a 61% ORR in patients with R/R CLL and a more modest effect in other B cell malignancies, including a 35.3% ORR in LPL/WM, 17.9% in MCL, 17.1% in FL, 11.8% in MZL, and no responses in DLBCL [197,204,208].